Halozyme Therapeutics (NASDAQ:HALO) Issues FY 2022 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) issued an update on its FY 2022 earnings guidance on Wednesday morning. The company provided EPS guidance of $2.050-$2.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.180. The company issued revenue guidance of $530 million-$560 million, compared to the consensus revenue estimate of $553.27 million.

Several research firms have recently commented on HALO. Zacks Investment Research raised shares of Halozyme Therapeutics from a strong sell rating to a hold rating and set a $37.00 price target for the company in a report on Monday, March 14th. StockNews.com lowered shares of Halozyme Therapeutics from a buy rating to a hold rating in a research note on Tuesday, April 19th. Finally, Piper Sandler lowered their price objective on shares of Halozyme Therapeutics from $43.00 to $42.00 in a research report on Wednesday, February 23rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Buy and an average price target of $47.83.

HALO stock opened at $42.98 on Wednesday. The company has a quick ratio of 7.45, a current ratio of 7.91 and a debt-to-equity ratio of 4.00. The company has a market capitalization of $5.92 billion, a price-to-earnings ratio of 15.63 and a beta of 1.32. Halozyme Therapeutics has a 12 month low of $31.36 and a 12 month high of $51.57. The firm has a 50 day moving average of $38.35 and a two-hundred day moving average of $37.09.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last posted its earnings results on Tuesday, February 22nd. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.04. The company had revenue of $102.00 million during the quarter, compared to the consensus estimate of $97.10 million. Halozyme Therapeutics had a net margin of 90.84% and a return on equity of 164.68%. On average, research analysts expect that Halozyme Therapeutics will post 1.99 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Halozyme Therapeutics by 0.7% during the 4th quarter. BlackRock Inc. now owns 19,439,863 shares of the biopharmaceutical company’s stock worth $781,676,000 after buying an additional 144,483 shares during the period. Allianz Asset Management GmbH boosted its holdings in shares of Halozyme Therapeutics by 4.5% during the 4th quarter. Allianz Asset Management GmbH now owns 586,274 shares of the biopharmaceutical company’s stock worth $23,575,000 after buying an additional 25,161 shares during the period. Deutsche Bank AG boosted its holdings in shares of Halozyme Therapeutics by 6.3% during the 4th quarter. Deutsche Bank AG now owns 111,307 shares of the biopharmaceutical company’s stock worth $4,476,000 after buying an additional 6,617 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Halozyme Therapeutics by 1.6% during the 4th quarter. California State Teachers Retirement System now owns 195,973 shares of the biopharmaceutical company’s stock worth $7,880,000 after buying an additional 3,170 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of Halozyme Therapeutics by 5.1% during the 4th quarter. Parametric Portfolio Associates LLC now owns 293,558 shares of the biopharmaceutical company’s stock worth $11,804,000 after buying an additional 14,233 shares during the period. 90.21% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics (Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Read More